{"abstract":"This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Option License Agreement to IntelliPanel Medical, LLC, a company having a place of business in Philadelphia, PA, to practice the inventions embodied in the following patent applications:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/05/19/2016-11769.html","cfr_references":[],"citation":"81 FR 31652","comment_url":null,"comments_close_on":"2016-06-03","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 3, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-11769","effective_on":null,"end_page":31652,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/05/19/2016-11769.xml","html_url":"https://www.federalregister.gov/documents/2016/05/19/2016-11769/prospective-grant-of-exclusive-start-up-option-license-anti-tnf-induced-apoptosis-atia-diagnostic","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-11769?publication_date=2016-05-19","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-05-19/2016-11769/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":105,"last_updated":"2026-04-05 00:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-05-19/pdf/2016-11769.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-11769.pdf?1463575557","publication_date":"2016-05-19","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/05/19/2016-11769.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T07:44:51Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":31652,"subtype":null,"title":"Prospective Grant of Exclusive Start-up Option License: Anti-TNF Induced Apoptosis (ATIA) Diagnostic Markers and Therapies","toc_doc":"Anti-TNF Induced Apoptosis Diagnostic Markers and Therapies","toc_subject":"Grants of Exclusive Start-up Option Licenses:","topics":[],"type":"Notice","volume":81}